Huons휴온스

Huons is profitable on a trailing basis but its shares have fallen sharply over the past year, and recent filings include a disclosure-related designation.

Huons reported trailing twelve-month revenue of about ₩608B and operating income of about ₩22B through H1 2026, both lower than its 2025 full-year levels of ₩621B and ₩46B. The share price closed at ₩17,370 on 23 October 2026, down 41.3% over one year and near its 52-week low of ₩17,110. The company is pursuing a merger and has presented early preclinical data for a Crohn's disease candidate.

What stands out

• Trailing operating margin is 3.6%, down from 7.3% in 2025 and 10.1% in 2023, and trailing net income of about ₩19B is well below 2025's ₩43B.
• Valuation metrics look low on paper, with P/E of 11, P/B of 0.6 and a dividend yield of 5.3%, but the data gives no analyst views on whether that is justified.
• The DCF-based fair value model gives a base of ₩51,504, a bear case of ₩18,850 and a bull case of ₩114,152, with the wide range reflecting high uncertainty.
• Trailing borrowings of about ₩158B exceed cash of about ₩49B, and liabilities are 60.4% of equity.
• On 23 September 2026 the company was notified of designation as an unfaithful disclosure entity over two cases of disclosure reversal, and on 21 October it was reported as not designated, with designation deferred.

What to watch

• Merger decision and shareholders' meeting, which have been amended several times since August 2026.
• Any further outcome of the unfaithful disclosure review and the deferred designation.
• Full-year 2026 results and whether margins recover from the trailing 3.6% level; the data does not include forecasts.